MediciNova, Inc. 10-Q Summary
Business Context and Reporting Period
MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for serious diseases. The filing covers the quarter and six months ended June 30, 2012. The company reported 16,163,565 common shares outstanding as of August 8, 2012.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2012 | Six Months Ended June 30, 2012 |
|---|---|---|
| Revenue | $493,623 | $684,797 |
| Research and development expense | $1.5 million | $3.4 million |
| General and administrative expense | $1.3 million | $3.5 million |
| Operating loss | $2.3 million | $6.2 million |
| Net loss | $2.3 million | $6.1 million |
| Basic and diluted loss per share | $0.14 | $0.38 |
| Net cash used in operating activities | Not separately provided | $7.3 million |
Revenue consisted of research and development services performed for Kissei Pharmaceutical under a $2.5 million non-refundable upfront-payment agreement relating to MN-221. The company recognized $0.5 million in the quarter and $0.7 million year to date; the remaining amount was recorded as deferred revenue.
Cash and cash equivalents were $7.3 million at June 30, 2012, down from $15.1 million at December 31, 2011. Total assets were $23.0 million and total liabilities were $5.2 million. Current liabilities included $1.8 million of deferred revenue. Stockholders’ equity was $17.9 million. The company reported no debt and no interest expense during the first half of 2012; its prior $15.0 million Oxford loan had been repaid in April 2011.
The filing does not present a conventional gross margin because cost of revenues was reported as zero. The company remains loss-making, with an accumulated development-stage deficit of $291.4 million at June 30, 2012.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased from zero to $493,623, and six-month revenue increased from zero to $684,797, due to the Kissei services agreement.
- Quarterly research and development expense declined from $2.0 million to $1.5 million; six-month expense declined from $4.7 million to $3.4 million. The decrease primarily reflected completion of the MN-221 CL-007 trial, partly offset by spending on the MN-221 COPD trial.
- Quarterly general and administrative expense declined from $1.7 million to $1.3 million, and six-month expense declined from $4.0 million to $3.5 million, primarily due to lower compensation and stock-based compensation costs.
- Quarterly net loss improved from $4.7 million to $2.3 million, while the six-month net loss improved from $10.3 million to $6.1 million. The prior-year periods included approximately $0.9 million and $1.6 million of interest expense, respectively.
- Operating cash use improved to $7.3 million in the first half of 2012 from $9.4 million in the first half of 2011, but cash declined by $7.8 million during the first half of 2012.
- In March 2012, MediciNova invested $680,000 for a 30% interest in Zhejiang Sunmy, a China-focused joint venture for MN-221. The required MN-221 sublicense had not been executed as of the filing date.
Guidance, Outlook, Risks, and Unusual Items
Management expects substantial operating losses to continue for at least the next several years. Based on its current operating plan and assuming no new clinical trials, management believed available working capital would fund operations through at least March 31, 2013. Management also stated that additional equity, debt, collaboration, or other financing will likely be needed.
The 176-patient Phase 2 MN-221-CL-007 asthma trial did not statistically meet its primary FEV1 endpoint. Management nevertheless cited reductions in hospital admissions, improved clinical symptoms, and a favorable safety profile. An FDA End-of-Phase 2 meeting was scheduled for the fourth quarter of 2012. An unfavorable outcome could delay or prevent further MN-221 development and impair the company’s ability to raise capital.
The MN-221 CL-012 Phase 1b/2a COPD trial had commenced enrollment and was expected to be completed in the third quarter of 2012. MN-166 development remained dependent on securing strategic collaboration or funding. Non-prioritized programs were being limited to activities necessary to preserve license rights or maximize value.
- Key risks include continued clinical and regulatory uncertainty, failure to obtain strategic partners or financing, potential dilution from future equity issuance, and possible termination of product license rights if funding is insufficient.
- The company’s cash balances exceeded FDIC-insured limits, although funds were primarily held in money market accounts and funds invested in U.S. government securities.
- A former employee litigation matter had been compelled to arbitration; discovery was ongoing and no arbitration date had been scheduled. Management did not expect a material adverse effect based on its current assessment.
- No material changes to previously disclosed risk factors were reported other than the added risk concerning an unsuccessful FDA End-of-Phase 2 meeting for MN-221.
- Management reported effective disclosure controls and no material change in internal control over financial reporting.
Investor Verification Checklist
- Verify the remaining balance and recognition schedule for the $2.5 million Kissei upfront payment and related deferred revenue.
- Review the complete results of the MN-221 CL-007 trial and the outcome of the planned FDA End-of-Phase 2 meeting.
- Assess the company’s cash runway against actual operating cash burn and the assumption that no new clinical trials will begin.
- Confirm future financing requirements, potential equity dilution, and the status of strategic partnerships for MN-221 and MN-166.
- Verify execution of the MN-221 sublicense to Zhejiang Sunmy and the joint venture’s funding and development obligations.
- Review outstanding options, warrants, and Series B preferred stock that could affect future ownership and dilution.